Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.
JAMASep 8, 2026
This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…
Key findings
- Median progression-free survival was 34.0 months for osimertinib plus chemotherapy versus 15.6 months for osimertinib alone.
- The hazard ratio for progression-free survival was 0.44, indicating a significant benefit for combination therapy.
- The incidence of grade 3 or higher treatment-related adverse events was higher in the combination group.